Grafa News and Videos — Page 701

Vera Therapeutics (NASDAQ:VERA) has reached an agreement with the U.S. Food and Drug Administration to accelerate the regulatory timeline for its experimental kidney disease treatment, clearing the path for an earlier analysis of pivotal Phase 3 data.

BeyondSpring (NASDAQ:BYSI) announced updated data from an investigator-initiated Phase 2 clinical trial evaluating a triple-combination therapy for patients with advanced lung cancer, demonstrating sustained overall survival and disease control in a difficult-to-treat population.

Saia (NASDAQ:SAIA) reported solid expansion across its core less-than-truckload (LTL) operational metrics for April and May 2026, driven by an acceleration in daily tonnage and ongoing improvements in freight weight profiles compared to the prior year.

Village Super Market (NASDAQ:VLGEA) reported a 1.6% increase in net sales for its fiscal 2026 third quarter, as resilient grocery demand and robust digital growth helped mitigate the operational disruptions caused by severe winter weather.

Victoria’s Secret (NYSE:VSCO) reported a 15% increase in first-quarter net sales, fueled by a sharp recovery in consumer demand that prompted the apparel retailer to lift its financial projections for the full fiscal year.

Watsco (NYSE:WSO) has finalized its acquisition of Jackson Supply Company, a prominent distributor of heating, ventilation, and air conditioning (HVAC) equipment, significantly expanding its operational reach across the fast-growing U.S. Sunbelt region.

Evogene (NASDAQ:EVGN) announced that a first-in-human Phase 1 clinical trial evaluating its experimental microbiome-based oncology therapy, BMC128, successfully met its primary safety endpoint when administered in combination with the immunotherapy drug Nivolumab.

Camtek (NASDAQ:CAMT) announced it has received more than $105 million in new multi-system orders for its semiconductor inspection and metrology equipment, extending the company’s business visibility well into the following year.

Travere Therapeutics (NASDAQ:TVTX) has entered into an exclusive licensing and collaboration agreement with Everest Medicines to develop and commercialize civorebrutinib, an experimental treatment targeting multiple immune-mediated rare kidney diseases.

Oddity Tech (NASDAQ:ODD) reported a 26% decline in first-quarter net revenue as a severe dislocation with its largest digital advertising partner drove customer acquisition costs sharply higher and eroded media efficiency.